These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38947224)

  • 1. A Health Technology Assessment Based on Chinese Guideline: Active Vitamin D and Its Analogs in the Treatment of Osteoporosis.
    Huang S; Li J; Hu X; Chen J
    Drug Des Devel Ther; 2024; 18():2593-2608. PubMed ID: 38947224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for active vitamin D and analogs in the treatment of osteoporosis.
    Nishii Y
    J Cell Biochem; 2003 Feb; 88(2):381-6. PubMed ID: 12520540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment.
    Ono Y
    J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol.
    Kubodera N
    Mini Rev Med Chem; 2009 Oct; 9(12):1416-22. PubMed ID: 19929815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
    Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
    Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of alfacalcidol for reducing increased risk of falls and fractures.
    Ringe JD; Schacht E
    Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.
    Schacht E; Dukas L; Richy F
    J Musculoskelet Neuronal Interact; 2007; 7(2):174-84. PubMed ID: 17627088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
    Ringe JD; Schacht E
    Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.
    Uenishi K; Tokiwa M; Kato S; Shiraki M
    Osteoporos Int; 2018 Mar; 29(3):723-732. PubMed ID: 29273827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management.
    Richy F; Deroisy R; Lecart MP; Hanssens L; Mawet A; Reginster JY
    Aging Clin Exp Res; 2005 Apr; 17(2):133-42. PubMed ID: 15977462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment.
    Orimo H; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():4-10. PubMed ID: 16142845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eldecalcitol: a review of its use in the treatment of osteoporosis.
    Sanford M; McCormack PL
    Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
    Hagino H
    Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
    Scharla SH; Schacht E; Lempert UG
    J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
    Ringe JD; Farahmand P; Schacht E
    Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis.
    Uchiyama Y; Higuchi Y; Takeda S; Masaki T; Shira-Ishi A; Sato K; Kubodera N; Ikeda K; Ogata E
    Bone; 2002 Apr; 30(4):582-8. PubMed ID: 11934649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.